# Why is Altimmune, Inc. (ALT) stock trending?

November 18, 2026

Rumor.io reads what investors post about Altimmune, Inc. on X, Reddit, Stocktwits and YouTube and uses AI to summarize it each day. Updated November 18, 2026. Source: https://rumor.io/stocks/nasdaq-alt/questions

What people say, Nov 19:

- Goldman Sachs increased its position in Altimmune, Inc. (ALT) by 12% last quarter.
- Several notable investors, including Two Sigma, Trails Edge Capital, Point72, Fidelity, and Citadel, increased their positions in ALT through 13F filings.
- The CEO's actions to protect shareholder value are unclear, with one post questioning the CEO's efforts to do so.

Altimmune, Inc. (ALT) has 0.25% of all stock attention on November 18, 2026, about 3.3x its 30-day average of 0.076%.

|  | Attention | 30-day average attention |
| --- | --- | --- |
| ALT | 0.25% | 0.076% |

Attention is the share of the likes, replies and reposts on posts about stocks.

## Is ALT stock sentiment bullish or bearish?

Sentiment on Altimmune, Inc. (ALT) is bearish on November 18, 2026: 43% of engagement on its posts is bullish, down from its 30-day average of 62%. That is below all stocks (56%) and the Healthcare sector (61%).

|  | Bullish | Bearish |
| --- | --- | --- |
| ALT | 43% | 57% |
| ALT, 30-day average | 62% | 38% |
| Healthcare sector | 61% | 39% |
| All stocks | 56% | 44% |

The share of the likes, replies and reposts on bullish posts and on bearish posts, of the posts that took a side.

### What is the bull case for ALT stock?

What the bulls say, Nov 18:

- The company's valuation is attractive, with the entire company being priced at 62% of total net cash/investments, potentially leading to a significant increase in value.
- The asset has a strong pipeline with multiple late-stage indications, including a phase 3 multibillion-dollar MASH market, which could lead to a best-in-class outcome.
- The company's management is perceived as being in control, and the author believes that the stock will experience a significant run in the coming years, potentially reaching $10 or more.

Bulls hold 43% of engagement on Altimmune, Inc. (ALT) posts on November 18, 2026.

### What is the bear case for ALT stock?

What the bears say, Nov 18:

- The management team's execution uncertainty and inability to complete EOP2 meeting and secure a partnership by Q1/Q2 could lead to further dilution and potential bankruptcy.
- The company's R&D cash burn is surging, and the lack of a big-pharma partner is a major concern, contributing to the stock's 50% decline in three months.
- The CEO's leadership and decision-making have been questioned, with some users expressing disgust and frustration with the stock's performance, and one user even joking about practicing diving skills if the stock continues to plummet.

Bears hold 57% of engagement on Altimmune, Inc. (ALT) posts on November 18, 2026.

## What are investors saying about ALT stock?

We train models to sort every post about Altimmune, Inc. into topics, then summarize what each group is saying. Each figure is the share of the engagement on ALT posts that went to that topic.

|  | Share of engagement | 30-day average share |
| --- | --- | --- |
| Technical Analysis: chart patterns and price levels | 4% | 4% |

### What does technical analysis say about ALT stock?

What people say about ALT's chart, Nov 18:

- The $ALT stock price is currently weak, with the author expecting it to drop below $1 or $0.50 after the next Triple Witching Day, and believes a reverse split is likely.
- The author believes the stock is oversold and expects a violent green candle, but notes that the price may drop further if there is no uptick in buying pressure.
- The author expects a significant move in the stock price in the coming months, and is waiting for a price level of around $1.37, considering it a capitulation point, with a buy target of around $130.

Posts about chart patterns and price levels drew 4% of the engagement on Altimmune, Inc. (ALT) posts on November 18, 2026, against a 30-day average of 4%.

## What is the latest news on ALT stock?

- [Altimmune, Inc. (ALT) Presents at American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2026 - Slideshow](https://seekingalpha.com/article/4968249-altimmune-inc-alt-presents-at-american-association-for-the-study-of-liver-diseases-aasld-the?source=feed_tag_us) (Seeking Alpha, 4d ago): 2026-11-14. The following slide deck was published by Altimmune, Inc.
- [Altimmune director Wayne Pisano buys $16,350 in company stock](https://www.investing.com/news/insider-trading-news/altimmune-director-wayne-pisano-buys-16350-in-company-stock-93CH-5027180) (Investing.com, 4d ago)
- [ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns](https://finance.yahoo.com/healthcare/articles/alt-q3-earnings-miss-stock-112200319.html) (Yahoo Finance, 5d ago)
- [Citizens reiterates Altimmune stock rating on expanding pemvidutide data](https://www.investing.com/news/analyst-ratings/citizens-reiterates-altimmune-stock-rating-on-expanding-pemvidutide-data-93CH-5024554) (Investing.com, 5d ago)
- [Altimmune: Still Too Late And Too Capital-Intensive](https://seekingalpha.com/article/4967358-altimmune-still-too-late-and-too-capital-intensive) (Seeking Alpha, 6d ago): Altimmune remains a Sell as pemvidutide lacks clear differentiation in the competitive MASH landscape. Read more on ALT stock here.

## Who is talking about ALT stock?

8% of engagement on Altimmune, Inc. (ALT) posts on November 18, 2026 comes from people new to posting about it, about level with a 30-day average of 6%.

|  | Newcomers | Regulars |
| --- | --- | --- |
| ALT | 8% | 92% |
| ALT, 30-day average | 6% | 94% |
| All stocks | 43% | 57% |

The share of the likes, replies and reposts on ALT posts that went to people new to posting about it and to regulars.

### What newcomers say (Nov 18)

- The newcomers are concerned about the disconnect between Altimmune's share price and its potential, with some suggesting the price will hit $1.00 by year's end.
- The focus is on CEO Jerry Durso's leadership, with some calling for his resignation due to concerns about the company's cash management and transparency.
- Newcomers are speculating about the company's future, with some discussing the possibility of a hostile takeover bid or a partnership, and others predicting a deal will be announced in 2027.

### What regulars say (Nov 19)

- The regulars are focused on the recent 12% increase in Goldman Sachs' position in Altimmune, Inc. ($ALT).
- There is a notable increase in positions by several institutional investors, including Two Sigma, Trails Edge Capital, Point72, Fidelity, and Citadel, with some increasing their holdings by 200-300%.
- The CEO's actions are being questioned, with one regular wondering what he is doing to protect shareholder value, and another suggesting that negotiations with a potential buyer could be in progress.

## How does ALT compare with other Healthcare stocks?

We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each figure is that share.

Altimmune, Inc. (ALT) got the 5th most attention on social media of the Healthcare stocks on November 18, 2026: 2.5% of the attention on Healthcare stocks. The others with the most attention were SLS (33%), CAPR (8%), AKAN (6.3%) and UNH (4.2%).

|  | Share of Healthcare attention |
| --- | --- |
| [ALT](https://rumor.io/stocks/nasdaq-alt) | 2.5% |
| [SLS](https://rumor.io/stocks/nasdaq-sls) | 33% |
| [CAPR](https://rumor.io/stocks/nasdaq-capr) | 8% |
| [AKAN](https://rumor.io/stocks/nasdaq-akan) | 6.3% |
| [UNH](https://rumor.io/stocks/nyse-unh) | 4.2% |

### Which stocks are discussed alongside ALT?

People who post about Altimmune, Inc. (ALT) most often also post about TERN - Terns Pharmaceuticals, Inc., VKTX, GPCR, MDGL, MTSR - Metsera, Inc. and ETNB - 89bio, Inc..

- [What are investors saying about TERN - Terns Pharmaceuticals, Inc. stock?](https://rumor.io/stocks/nasdaq-tern)
- [What are investors saying about VKTX stock?](https://rumor.io/stocks/nasdaq-vktx): The company's lead molecule has substantial value today, and the rest of the company, net of cash, is not worth close to $1B.
- [What are investors saying about GPCR stock?](https://rumor.io/stocks/nasdaq-gpcr)
- [What are investors saying about MDGL stock?](https://rumor.io/stocks/nasdaq-mdgl)
- [What are investors saying about MTSR - Metsera, Inc. stock?](https://rumor.io/stocks/nasdaq-mtsr)
- [What are investors saying about ETNB - 89bio, Inc. stock?](https://rumor.io/stocks/nasdaq-etnb)

## What is Rumor.io?

Prices move on what people believe. Rumor.io measures what they are saying: it reads public posts about stocks, ETFs and crypto on X, Reddit, Stocktwits and YouTube, and reports what investors are talking about.

- What we read: 1.6 billion public posts about 7,500+ stocks, 6,600+ ETFs and 880+ cryptocurrencies, back to 2009.
- What we throw away: Social media is noisy. Our filters remove spam and bots, posts where the name means something else (Apple the fruit), and tickers that two assets share.

The summaries on this page are written by AI from public posts. The one under the heading is from the posts of November 19, 2026, and each of the others shows its own date. Updated November 18, 2026, the date of the oldest. The figures are counts of the posts and the reactions to them. They show what people are saying, which is not the same as what is true, and they do not predict a price.

Attention is an asset's share of the engagement on posts about all stocks. Engagement is the likes, replies and reposts a post receives. [How each metric is counted](https://rumor.io/docs/metrics). [More about Rumor.io](https://rumor.io).
